a-溴-2-甲基苯基乙酸 | 29302-73-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: a-溴-2-甲基苯基乙酸
• 英文名称: (+/-)-2-bromo-o-tolyl-acetic acid
• 英文别名: 2-bromo-2-(o-tolyl)acetic acid；α-bromo-(2-methylphenyl)acetic acid；methyl-α-bromophenylacetic acid；α-Brom-2-methylphenylessigsaeure；Bromo(2-methylphenyl)acetic acid；2-bromo-2-(2-methylphenyl)acetic acid
• CAS: 29302-73-6
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: ADJAWAHSDBSEIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  丙醇 、 a-溴-2-甲基苯基乙酸 在 对甲苯磺酸 作用下， 以77%的产率得到propyl (+/-)-2-bromo-o-tolyl-acetate
  参考文献：
  名称：

  Resolution of 2-bromo-o-tolyl-carboxylic acid by transesterification using lipases from Rhizomucor miehei and Pseudomonas cepacia

  摘要：

  Several lipases were screened for their ability to catalyze the enantioselective transesterification of 2-bromo-o-tolyl acetic acid. Amongst the preparations tested, the lipases from Rhizomucor miehei and Pseudomonas cepacia were selected. The best enantioselectivity was obtained with Rhizomucor miehei lipase immobilized on polypropylene (E = 11.3), which was more stereoselective than the free form. Hydrophobic solvents with log P higher than 2.5 were the most suitable giving the highest E-values. In addition, factors such as the water activity and the reaction temperature had little effect on the resolution of the racemic mixture. The selectivity of the enzymes with respect to the substrate was also only weakly affected by the structure of the leaving alcohol except in the case of the iso-propyl group, which causes high steric hindrance. Operating conditions under reduced pressure were defined to resolve the racemic mixture with immobilized Rhizomucor miehei lipase. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00432-3
• 作为产物：
  描述：

  邻甲基苯乙酸 在 硫酸 、 氢溴酸 作用下， 以 水 为溶剂， 反应 3.0h， 以39%的产率得到a-溴-2-甲基苯基乙酸
  参考文献：
  名称：

  Resolution of 2-bromo-o-tolyl-carboxylic acid by transesterification using lipases from Rhizomucor miehei and Pseudomonas cepacia

  摘要：

  Several lipases were screened for their ability to catalyze the enantioselective transesterification of 2-bromo-o-tolyl acetic acid. Amongst the preparations tested, the lipases from Rhizomucor miehei and Pseudomonas cepacia were selected. The best enantioselectivity was obtained with Rhizomucor miehei lipase immobilized on polypropylene (E = 11.3), which was more stereoselective than the free form. Hydrophobic solvents with log P higher than 2.5 were the most suitable giving the highest E-values. In addition, factors such as the water activity and the reaction temperature had little effect on the resolution of the racemic mixture. The selectivity of the enzymes with respect to the substrate was also only weakly affected by the structure of the leaving alcohol except in the case of the iso-propyl group, which causes high steric hindrance. Operating conditions under reduced pressure were defined to resolve the racemic mixture with immobilized Rhizomucor miehei lipase. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00432-3

文献信息

• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2011123937A1

  公开（公告）日：2011-10-13

  The present teachings provide a compound represented by Strutural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

  本教学提供了一种由结构式(I)表示的化合物，或其药用可接受的盐。还描述了一种药物组合物及其使用方法。
• NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS
  申请人：Ackermann Jean

  公开号：US20080103183A1

  公开（公告）日：2008-05-01

  Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.

  具有以下公式的化合物以及其药学上可接受的盐和酯，其中R1至R6具有权利要求1中给定的含义，可以用作药物组合物的形式。
• POLYMERISATION USING CHAIN TRANSFER AGENTS
  申请人：Perrier Sebastian

  公开号：US20090215965A1

  公开（公告）日：2009-08-27

  The invention provides a process for synthesising functionalised chain transfer polymers of Formula (1) or Formula (2) using thiocarbonyl thio compounds as chain transfer agents. Why R1 is a moiety comprising a functional group; Q is obtained from an olefinically unsaturated monomer; R′ is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, an aromatic saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more substituents, amino alkyl, cyanoalkyl, hydroxylalkyl, saturated and unsaturated amido; an organometallic species, a polymer chain and any of the foregoing substituted with one or more CN or OH groups; q=an integer of at least 2; p=an integer of at least 1. Chain transfer agents and polymers produced by the method are also provided.

  该发明提供了一种合成功能化链转移聚合物的方法，使用硫代羰基硫化合物作为链转移剂，其化学式为(1)或(2)。其中，R1是包含功能基团的基团；Q是从烯烃不饱和单体获得的；R′选自包括烷基、取代烷基、烷氧基、取代烷氧基、芳香饱和或不饱和碳环或杂环环，可选地取代一个或多个取代基，氨基烷基、氰基烷基、羟基烷基、饱和和不饱和酰胺的基团；有机金属物种、聚合物链和上述任何一种基团，其中取代有一个或多个CN或OH基团；q至少为2的整数；p至少为1的整数。该方法还提供了链转移剂和由该方法产生的聚合物。
• [EN] SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS<br/>[FR] COMPOSES PHENYLES SUBSTITUES UTILISES COMME ANTAGONISTES DE L'ENDOTHELINE
  申请人：RHONE POULENC RORER LIMITED

  公开号：WO1996022978A1

  公开（公告）日：1996-08-01

  (EN) Compounds of formula (I) are described, wherein: R1 is CN, CH2CN, CH=CHCN, CHO, or CH=CHCO2H; R2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio in which each of the aryl and heteroaryl moieties is optionally substituted; R3 is halogen; R4 is optionally substituted aryl or optionally substituted heteroaryl; R5 is carboxy or an acid isostere; X is oxygen or sulphur; and n is zero or 1; and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.(FR) L'invention porte sur des composés de la formule (I), leurs oxydes d'azote, leurs précurseurs de médicament ainsi que les sels acceptables du point de vue pharmaceutique qui en sont issus. Dans cette formule, R1 est CN, CH2CN, CH=CHCN, CHO, ou CH=CHCO2H; R2 est aryle alcoxy inférieur, hétéroaryle alcoxy inférieur, aryle alkylthio inférieur ou hétéroaryle alkylthio inférieur, dans lequel chacun des fragments aryle ou hétéroaryle peut, éventuellement, être substitué; R3 est halogène; R4 est éventuellement aryle substitué ou hétéroaryle substitué; R5 est carboxy ou un isostère acide; X est oxygène ou soufre et n vaut zéro ou 1. Ces composés, qui ont une activité antagoniste de celle de l'endothéline, ont montré leur efficacité en tant que préparations pharmaceutiques

  化合物的公式（I）被描述，其中：R1为CN，CH2CN，CH=CHCN，CHO或CH=CHCO2H; R2为芳基低烷氧基，杂芳基低烷氧基，芳基低烷硫基或杂芳基低烷硫基，其中每个芳基和杂芳基可以选择性地被取代; R3为卤素; R4为可选择性取代的芳基或可选择性取代的杂芳基; R5为羧基或酸异构体; X为氧或硫; n为零或1; 以及它们的N-氧化物和前药，以及药学上可接受的盐。这些化合物具有内皮素拮抗剂活性，可用作制药用途。
• Novel piperidine derivatives for use in the treatment of chemokine medicated disease states
  申请人：Luckhurst Christopher

  公开号：US20060040984A1

  公开（公告）日：2006-02-23

  The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一个公式(I)的化合物：其中变量在此定义；以及制备这种化合物的过程；以及将这种化合物用于治疗趋化因子（例如CCR3）或H1介导的疾病状态的用途。